Cancer Advance
Date: Location: Cost:
April 11, 2017 Harvard Medical School - Joseph B. Martin Conference Center
77 Avenue Louis Pasteur
Boston, MA 02115

Starting at $1950

 

Dress Code:
Business Attire

Register

Cancer Advance Boston - April 11, 2017

Co-hosts: Jörn Aldag, Robert Bazemore, Barry Brooks, Paul Biondi, Pablo Cagnoni, Chip Clark, George Demetri, John DeYoung, Giulio Draetta, Robert Forrester, Edward Garmey, Chris Guiffre, JC Gutierrez-Ramos, Jim Healy, John Herrmann, Rachel Humphrey, Arthur Krieg, Jonathan Lewis, Niven Narain, Bob Oliver, Ferran Prat, Robert Radinsky, Oliver Rosen, Bob Silverman, Kristine Swiderek, Daniel Teper, Pascal Touchon, Beth Trehu, Guillaume Vignon, Markus Warmuth

Time Agenda
7:15-8:15 am

Registration and Networking Breakfast

8:15-8:30 am

Welcome and Opening Remarks
Giulio Draetta
VP, Therapeutics Discovery, MD Anderson Cancer Center; John Haurum, CEO, F-Star Biotechnology; Henning Steinhagen, EVP, Drug Discovery & Development, Aptuit; Bob Oliver, President & CEO, Otsuka Pharmaceuticals; Robert Forrester, President & CEO, Verastem

8:30-9:00 am

Oncology 2017: Trends to Watch
Denise Faustman, Director, Immunobiology, Massachusetts General Hospital; John Hohneker, EVP & Head, R&D, FORMA Therapeutics; Bob Oliver, President & CEO, Otsuka Pharmaceuticals; James Oliviero, President & CEO, Checkpoint Therapeutics; Maria Whitman, Managing Partner, ZS Associates
Moderator: Robert Forrester, President & CEO, Verastem

9:00-9:30 am

Financing Innovation in the Oncology Market
Carolyn Green, Executive Director, Strategic InvestmentsPfizer; John Haurum, CEO, F-Star Biotechnology; Martin Lehr, President & CBO, Context Therapeutics; Jonathan Lewis, CEO, Samus Therapeutics
Moderator: Pablo Cagnoni, President & CEO, Tizona Therapeutics

9:30-10:00 am

Optimizing Value to Drive Reimbursement
Marcia Fournier, Founder & CEO, Bioarray Genetics; Richard Popiel, EVP & CMO, Regence BlueCross BlueShield
Moderator: Jim CocciaVP, US Market Access, Oncology, Takeda

10:00-10:30 am

Networking Break

10:30-11:00 am

Novel Clinical Trial Design: Implementing Biomarkers and Diagnostics
Peter Blume-Jensen, CSO, XTuit; Giulio Draetta, VP, Therapeutics Discovery, MD Anderson Cancer Center; Rachel Humphrey, CMO, CytomX; Oliver Rosen, CMO, Deciphera; Peter Smith, CSO, H3 Biomedicine
Moderator: Edward GarmeyCMO, Bicycle Therapeutics

11:00-11:30 am

Leveraging Liquid Biopsies and New Technologies
Paul Beresford
, CBO, Biodesix; Richard Lanman CMO, Guardant Health; Jimmy Lin, CSO, Oncology, Natera
Moderator: George Demetri, SVP, Experimental Therapeutics, Dana Farber Cancer Institute

11:30-12:00 pm

Innovative Deal Structures in Oncology
Andrew Curtis, Head, Strategy, Affimed Therapeutics AG; John DeYoung, VP, WWBD, Pfizer; Shalabh Gupta, President & CEO, Globavir Biosciences; Robert Radinsky, VP, Oncology Scientific Innovation, Janssen Research & Development; Guillaume VignonHead, Immuno-Oncology Licensing & BD, Merck KGaA
Moderator: Bob SilvermanHead, Externalized Drug Discovery Partnering, Roche

12:00-1:00 pm

Networking Lunch 

1:00-1:30 pm

Maximizing Research Collaborations and Tech Transfer
Anne Deconinck, Executive Director, MIT Koch Institute; Philip GotwalsExecutive Director, Oncology Research, Novartis; Daniel O'Connor, President & CEO, Advaxis; Gary Sclar, VP, Innovations, Dana Farber Cancer Institute; Robert Spiegel, CMO, PTC Therapeutics
Moderator: Joern-Peter HalleSVP, Head, External Innovation, EMD Serono

1:30-2:00 pm

Commercialization and Manufacturing: Strategies for Success
Art Fratamico, CBO, Galera Therapeutics; Dinesh Purandare, SVP, Global Oncology, Radius Health; Cynthia SchwalmEVP & President, North American Commercial Operations, IPSEN; Alan Wright, Chief Medical Officer, Roche Diagnostics
Moderator: Pascal TouchonSVP Global Head, Strategy & BD, Novartis Oncology

2:00-2:30 pm

Immunotherapy Trends & Challenges
Sudhir Agrawal, President, Research, Idera Pharmaceuticals; Chip Clark, President & CEO, Genocea Biosciences; Pamela Contag, CEO, ConcentRx Inc.; Björn Frendéus, CSO, BioInvent; Kristine Swiderek, CSO, OncoResponse
Moderator: Jonathan PachterCSO, Verastem

2:30-3:00 pm

Networking Break

3:00-3:30 pm

Advances in Combination Therapy
Errik Anderson, Co-Founder, President & COOCompass Therapeutics; Jeffrey BachaPresident, CEO, & Co-Founder, DelMar Pharmaceuticals; Steven Fruchtman, CMO, Onconova; Arthur Krieg, Founder & CEO, Checkmate Pharmaceuticals; Patrick Tricoli, CEO, Nanobiotix USA
Moderator: Ferran Prat, VP, Strategic Industry Ventures, MD Anderson Cancer Center

3:30-4:00 pm

Partnering and M&A Outlook
David Giljohann, CEO, Exicure; Jim HealyManaging General Partner, Sofinnova Ventures; Matt Roden, Head, Strategic Corporate Development, Bristol-Myers Squibb; Henning Steinhagen, EVP, Discovery & Development, Aptuit; Daniel Teper, CEO, Immune Pharmaceuticals
Moderator: Justin Renz, EVP, CFO, & Treasurer, Karyopharm

4:00-4:30 pm

The Next 10 Years: Predictions and Wishes
Andrew Allen, President & CEO, Gritstone Oncology; Robert Bazemore, President & CEO, Epizyme; JC Guitierrez-Ramos, CEO, Synlogic Therapeutics; John Herrmann, Expert Partner & SVP, OncologyCatenion; Symantha Melemed, Global Product Team Leader, Eli Lilly
Moderator: Tim Clackson, CSO & President, R&D, ARIAD 

4:30-4:45 pm

Presentation of the Oncology Innovation of the Year Award

4:45-6:00 pm

Networking Cocktails and Hors d'oeuvres

Premier Sponsors: (see all sponsors)

<